针对MHC-E作为疫苗和免疫疗法的新战略
Klaus Früh1, Persephone Borrow2, Geraldine M Gillespie2
1Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA. fruehk@ohsu.edu.
Nature reviews. Immunology
|September 3, 2025
概括
主性组织相容性复合物类E (MHC-E) 蛋白调节像自然杀手细胞 (NK) 和T细胞这样的免疫细胞. 针对MHC-E相互作用提供了新的癌症和传染病免疫疗法和疫苗的潜力.
科学领域:
- 免疫学
- 分子生物学
- 疫苗学
背景情况:
- 主性基因相容性复合物E类 (MHC- E) 是一种与自然杀手 (NK) 和T细胞受体相互作用的保存型非多态蛋白.
- 在抗慢性病毒感染和癌症的免疫反应中,MHC- E通过激活抑制和激活受体发挥作用.
研究的目的:
- 审查MHC-E在先天性和适应性免疫中的多方面的作用.
- 探索基于MHC-E的免疫疗法和传染病和癌症疫苗的潜力.
主要方法:
- 对MHC- E生物学,NK细胞相互作用,T细胞反应和免疫治疗策略的现有文献的审查.
- 对MHC-E的抗原呈现能力及其在MHC-E受限T细胞反应中的作用的分析.
主要成果:
- 在NK细胞和T细胞上接触抑制和激活受体,影响免疫细胞的激活.
- 向MHC- E抑制受体相互作用可以增强NK和T细胞的激活,从而改善抗瘤免疫力.
- 对于某些疾病,MHC-E受限的CD8+T细胞可能比传统的MHC分子受限的细胞具有更广泛的疗效.
结论:
- MHC-E能够调节与生俱来的和适应性免疫,独立于MHC单元型,为通用疫苗和免疫疗法提供了机会.
- 治疗利用MHC-E是有前途的,但仍处于早期阶段,强调需要对其生物学进行进一步研究.
相关概念视频
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Antigens Involved in Adaptive Immunity
667
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
667
Cancer Vaccines
509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
Antigen Processing Pathways
1.3K
MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
MHC Class I: Presenting Endogenous...
1.3K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K


